Publications by authors named "B Wildemann"
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD.
J Neurol Neurosurg Psychiatry
December 2024
Background: Recurrent attacks in neuromyelitis optica spectrum disorders (NMOSDs) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can lead to severe disability. We aimed to analyse the real-world use of immunotherapies in patients with NMOSD and MOGAD, focusing on changes in treatment strategies, effects on attack rates (ARR) and risk factors for attacks.
Methods: This longitudinal registry-based cohort study included 493 patients (320 with aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive NMOSD (65%), 44 with AQP4-IgG seronegative NMOSD (9%) and 129 MOGAD (26%)) with 1247 treatments from 19 German and one Austrian centre from the registry of the neuromyelitis optica study group (NEMOS).
Objective: In this multicentric study, we were interested in the vision-related quality of life and its association with visual impairment in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in comparison to multiple sclerosis (MS) and healthy controls.
Methods: We analysed extracted data from the German NEMOS registry including National Eye Institute Visual Function Questionnaire (NEI-VFQ) scores, high and low contrast visual acuity (HCVA, LCVA), visually evoked potentials (VEP) and the scores for the expanded disability status scale (EDSS) and other neurological tests which assessed their disease-related impairment. The mean follow-up time of our patients was 1.
Article Synopsis
- - The study investigates the relationship between the Epstein-Barr virus (EBV) and multiple sclerosis (MS) by analyzing the presence of antibodies against EBV and other common microbes in patients with MS, revealing a universal EBV seroprevalence among participants.
- - A total of 50 MS patients were tested for antibodies in their cerebrospinal fluid (CSF) and serum, finding that while all patients were EBV positive, the production of specific antibodies in the CSF was significantly lower for EBV compared to other viruses like measles and VZV.
- - The results indicate that even though almost all MS patients have been exposed to EBV, the actual production of antibodies against EBV in the central
Background: Incomplete attack remission is the main cause of disability in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Apheresis therapies such as plasma exchange and immunoadsorption are widely used in neuroimmunology. Data on apheresis outcomes in MOGAD attacks remain limited.
View Article and Find Full Text PDFAddressing the Generalizability of AI in Radiology Using a Novel Data Augmentation Framework with Synthetic Patient Image Data: Proof-of-Concept and External Validation for Classification Tasks in Multiple Sclerosis.
Radiol Artif Intell
November 2024
Article Synopsis
- AI models usually struggle when applied to new datasets after being developed, leading to lower performance.
- This study explored the use of a data augmentation method through generative adversarial networks (GAN) to create synthetic patient images, aiming to enhance the AI model's ability to generalize across different datasets.
- Results showed that models using synthetic data achieved much better performance on external tests compared to those that did not, indicating that this approach could be beneficial in other medical imaging tasks as well.*